Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Thea Pharma, Inc.
WARNING LETTER
•Thea Pharma, Inc.•July 15, 2025

Thea Pharma, Inc. – FDA Warning Letter, Jul 15, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a warning letter to iVIZIA, located at 303 Wyman Street, Suite 205, Waltham, MA, on July 9, 2025, following a review conducted on August 29, 2024. The review focused on the labeling and marketing of the company"s IVIZIA sterile lubricant eye drops, available for purchase online without a prescription. The FDA identified significant regulatory violations under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The primary issue is that the IVIZIA eye drops are classified as an unapproved new drug, violating sections 505(a) and 301(d) of the FD&C Act. The product is intended for use as an ophthalmic demulcent, but it does not conform to the Over-the-Counter (OTC) monograph M018 for ophthalmic drug products. Specifically, the active ingredients, hyaluronic acid and trehalose, are not permitted for OTC monograph ophthalmic demulcent drug products, rendering the product non-compliant with the applicable conditions for lawful marketing.

Additionally, the product is deemed misbranded under section 502(ee) of the FD&C Act because it is marketed as a nonprescription drug without meeting the necessary regulatory requirements.

The FDA requires iVIZIA to cease the introduction or delivery of this unapproved and misbranded drug into interstate commerce. The company must take corrective actions to address these violations and ensure compliance with the FD&C Act to avoid further regulatory action.

Company
Thea Pharma, Inc.
Inspection date
July 15, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Tina Smith (Director)
  • Chrysoula Koukoutsis
View Company Profile

ID · 1552af9c-3927-4c4a-bb53-059617e71aba

Violation Codes10
21 U.S.C. 331(a)21 U.S.C. 331(d)21 U.S.C. 321(g)(1)(B)21 U.S.C. 35521 U.S.C. 352(ee)21 U.S.C. 321(g)(1)(C)21 U.S.C. 355h21.U.S.C. 355(a)21 U.S.C. 321(p)21 CFR 201.128

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Thea Pharma, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.